1. Generics Bulletin

Vanda Falls Again As Teva, FDA Win Judgment In ‘Unlawful’ Tasimelteon Approval Case

Originator Argued That Teva’s Hetlioz ANDA Improper Due To Braille Omission On Label

 
• By Dean Rudge

A month after Vanda failed to win a trade secrets case against the US FDA corresponding to generic approvals for its brands Hetlioz and Fanapt, the originator has again fallen, this time to the agency and Teva in the alleged unlawful approval of the Israeli firm’s generic Hetlioz product.

Hand push red Red Cross mark to choose cancellation item , Approve and reject business and document
(Shutterstock)

A US district court in Washington D.C. has ruled in favor of Teva in Vanda Pharmaceuticals’ bid for summary judgment arguing that the US Food and Drug Administration’s approval of Teva’s generic version of the originator’s Hetlioz (tasimelteon) was unlawful, marking another defeat for serial litigator Vanda.

Having joined the suit shortly after it was filed by Vanda against the FDA in 2023, Teva has seen its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Products

Aeon Expects Imminent Data On Botox Biosimilar

 
• By Dave Wallace

Aeon Biopharma says it expects to complete primary structure and select functional analyses for its ABP-450 proposed biosimilar to Botox by the end of the current quarter, ahead of a meeting with the FDA in late 2025 to discuss next steps.

Viatris Locks Cipla Out Of Generic Yupelri Market Until 2039

 
• By Dean Rudge

Cipla has reached a settlement with Theravance Biopharma and Viatris regarding its proposed generic version of Yupelri (revefenacin) once-daily nebulized inhalation solution. Under the agreement, Cipla will not introduce its product into the US market prior to April 2039.

Vanda Slams FDA ‘Generic Bias’ As It Again Seeks To Undo Hetlioz ANDA Approvals

 
• By Dave Wallace

In its latest attempt to curtail generic versions of Hetlioz, Vanda Pharmaceuticals has called on US FDA commissioner Marty Makary to reverse a previous agency decision upholding two ANDA approvals, claiming an “unacceptable culture of bias toward approving generic drugs” at the FDA.